Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 14, 2025 11:01 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Umecrine Cognition säkrar SEK 24,6 miljoner till den pågående kliniska utvecklingen av golexanolon

STOCKHOLM, 14 juli 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition har genomfört en kapitalanskaffning om SEK 24,6 miljoner genom ett...
July 14, 2025 11:01 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company Umecrine Cognition raises MSEK 24.6 for the ongoing clinical development of golexanolone

STOCKHOLM, SWEDEN – July 14, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the portfolio company Umecrine Cognition has raised SEK 24.6 million through a convertible...
July 14, 2025 02:00 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Modus Therapeutics har slutfört rekryteringen i del 1 av sin fas 2a-studie med sevuparin

STOCKHOLM, SVERIGE 14 juli 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Modus Therapeutics har slutfört patientrekryteringen enligt tidsplan till del 1 av...
July 14, 2025 02:00 ET | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in part 1 of its phase 2a study with sevuparin

STOCKHOLM, SWEDEN July 14, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has completed patient enrollment on schedule to part 1...
July 03, 2025 01:00 ET | Source: Karolinska Development AB (publ)

Karolinska Development får uppdatering från Organon gällande OG-6219

STOCKHOLM, 3 juli 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att bolaget mottagit en uppdatering från Organon gällande utvecklingen av läkemedelskandidaten OG-6219, som...
July 03, 2025 01:00 ET | Source: Karolinska Development AB (publ)

Karolinska Development receives update from Organon concerning OG-6219

STOCKHOLM, SWEDEN – July 3, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces an update from Organon on the development of the drug candidate OG-6219, acquired by Organon...
June 30, 2025 04:42 ET | Source: Karolinska Development AB (publ)

Karolinska Development avyttrar aktier i portföljbolaget OssDsign

STOCKHOLM, SVERIGE 30 juni 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) avyttrar resterande aktier i portföljbolaget OssDsign och stärker därmed investmentbolagets likviditet. Avyttringen...
June 30, 2025 04:42 ET | Source: Karolinska Development AB (publ)

Karolinska Development divests shares in portfolio company OssDsign

STOCKHOLM, SWEDEN, June 30, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) divests its remaining shares in the portfolio company OssDsign and thereby strengthens the investment company’s...
June 27, 2025 10:49 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Modus Therapeutics genomför fullt säkerställd företrädesemission om 28,3 miljoner kronor

STOCKHOLM, SVERIGE 27 juni 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Modus Therapeutics genomför en fullt säkerställd företrädesemission av units om...
June 27, 2025 10:49 ET | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company Modus Therapeutics carries out a fully secured rights issue of SEK 28.3 million

STOCKHOLM, SWEDEN June 27, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics carries out a fully secured rights issue of units of...